MEDTRONIC HEART VALVES DIVISION ENVEO R DELIVERY SYSTEM; AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIV
|
Back to Search Results |
|
Model Number ENVEOR-N-US |
Device Problem
Device Dislodged or Dislocated (2923)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 11/10/2016 |
Event Type
malfunction
|
Manufacturer Narrative
|
Continuation of d10: product id evolutr-34-us (serial: (b)(6); product type: 0195-heart valves; implant date (b)(6) 2016.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Event Description
|
Medtronic received information that during implant of this transcatheter bioprosthetic valve, the patient had a pre-operative mean gradient of 39 mmhg and a peak gradient of 63 mmhg.No pre-implant or post-implant balloon aortic valvuloplasty (bav) was performed. the bioprosthetic valve crossed the native valve and was being slowly deployed when it dislodged superiorly.The valve was recaptured in the descending aorta and repositioned across the valve.Again, slow deployment was carried out and again the valve dislodged superiorly.Recapture for the second time was completed.The bioprosthetic valve was placed across the native valve.Pacing at 120 beats per minute was carried out and the valve was deployed at a good landing position.Implant depth was not documented. the patient had a post-procedure mean gradient of 9 mmhg and a peak gradient of 16 mmhg.No adverse patient effects were reported.
|
|
Manufacturer Narrative
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Manufacturer Narrative
|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
Event Description
|
Additional information was received that during the valve implant, the deployment starting point was mid pigtail.
|
|
Search Alerts/Recalls
|
|
|